![Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. - Abstract - Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. - Abstract -](https://europepmc.org/articles/PMC4769326/bin/gr2.jpg)
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. - Abstract -
![A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c19de62e-0074-4efb-ac2a-60e3ba3eb19f/gr6_lrg.jpg)
A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry
![A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0276e218-a0a2-4c49-8635-73226085b5d8/gr3_lrg.jpg)
A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry
![Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. - Abstract - Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. - Abstract -](https://europepmc.org/articles/PMC4769326/bin/gr1.jpg)
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. - Abstract -
![Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry | PNAS Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry | PNAS](https://www.pnas.org/content/94/6/2339/F1.large.jpg)
Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry | PNAS
Protein subcomplexes in the GIC preparation. Left, GICs were isolated... | Download Scientific Diagram
![Protein subcomplexes in the GIC preparation. Left, GICs were isolated... | Download Scientific Diagram Protein subcomplexes in the GIC preparation. Left, GICs were isolated... | Download Scientific Diagram](https://www.researchgate.net/profile/Felix-Wieland-3/publication/11930552/figure/fig7/AS:668611404374016@1536420789016/Protein-subcomplexes-in-the-GIC-preparation-Left-GICs-were-isolated-in-the-presence-of_Q640.jpg)
Protein subcomplexes in the GIC preparation. Left, GICs were isolated... | Download Scientific Diagram
![References in Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial - The Lancet Oncology References in Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/241b87a8-4bab-4585-bcf9-4d529b2cab16/gr3_lrg.gif)
References in Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial - The Lancet Oncology
![A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fe05a88c-82e7-49de-86dc-6035c39a11ed/gr2_lrg.jpg)